What are some common signs that suggest a cancer patient may be developing delirium? In this episode, we explore the complex issue of delirium in advanced cancer patients. We discuss important considerations regarding medication management, the importance of distinguishing terminal from reversible delirium, and the role of antipsychotics and benzodiazepines in treatment. Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer Management of Delirium in Patients With Cancer

In this episode, we discuss the treatment of agranulocytosis or neutropenia in patients on clozapine therapy, a rare yet serious scenario that clinicians may encounter. We delve into the possibility of rechallenging clozapine treatment after such an event and explore the use of colony-stimulating factors. What's the likelihood of agranulocytosis while prescribing clozapine long term? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 53 The Impact of Colony-Stimulating Factor on Clozapine Rechallenge Outcomes

In this episode, we delve into the management of anxiety in cancer patients, including the effective psychotherapeutic interventions and pharmacologic options for treating anxiety in this vulnerable group. The episode also touches on the importance of cultural sensitivity and patient education when managing anxiety in cancer patients. Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer Treating Anxiety Disorders in Patients With Cancer

In this podcast episode, Dr. David Rosenberg explores practical strategies to asess and manage common antidepressant side effects in the pediatric population. Get useful takeaways regarding activation, insomnia, withdrawal symptoms, and more. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 13 Managing Adverse Effects of Antidepressants in Youth

In this podcast episode, Jaroslava Salman, M.D., discusses the treatment options for depressed patients with cancer. Stay a step ahead in your practice with practical tips on which psychotherapies are helpful, which antidepressants to use and for how long, what to be mindful of, and even insights into prescribing stimulants. Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer Treating Depressive Disorders in Patients With Cancer

In this podcast episode, Dr. Vivien Burt delves into a study on brexanolone for women with postpartum depression, anxiety, and insomnia. Listen in and find out the effect and time frame of brexanolone on these symptoms. Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 53 Effect of Brexanolone on Postpartum Depressive Symptoms, Anxiety, and Insomnia

In this podcast, Dr. David Rosenberg offers practical insights into treatment optimization for youth with tic disorders. Listen in and find out which treatment modality takes precedence, which factors need to be considered, how long to use medication, and more. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CMEs: Tic Disorders in Children and Adolescents Treatment Optimization for Tic Disorders

In this podcast, Dr. David Rosenberg expertly addresses the questions on what to do when your adolescent patient has ADHD but uses cannabis. Should you prescribe stiimulants or not? And what if they just want stimulants for better test scores? What do you do? Listen in as Dr. Rosenberg offers useful takeaways to help you with these (all too common) dilemmas. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 12 Prescribing Stimulants for Youth With ADHD and Co-Occurring Cannabis Use

In this podcast, Dr. David Rosenberg delves into tic disorders and psychiatric comorbidities in youth. This includes ADHD, OCD, anxiety and depression, and disruptive behaviors. Jump in and listen to practical treatment options for these cases, and stay one step ahead in your clinical practice. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Tic Disorders in Children and Adolescents Tic Disorders and Psychiatric Comorbidities

CANMAT presents a spectrum approach to mixed states. In this podcast, Dr. Jim Phelps delves into this and the DSM-5 approach, where mixed states became a specifier that can be added to a diagnosis of unipolar depression, effectively creating a spectrum approach to the diagnosis of mixed mood disorders. So, what’s a clinician to do treatment-wise? Should we or should we not use antidepressants when 4 specific symptoms are present? Find the answer to these and other questions in this podcast. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 52 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Recommendations for the Management of Patients With Bipolar Disorder With Mixed Presentations

In this podcast episode, Dr. David Rosenberg provides a much-needed understanding of tic disorders in children and adolescents. Listen in to learn what a typical course of this disorder could look like, why you may not need to substitute methylphenidate in these patients, what happens when patients supress tics, and much more. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Tic Disorders in Children and Adolescents Understanding Tic Disorders

In this podcast, Dr. David Rosenberg explores a review on metformin for youth on SGAs. Is it effective in mitigating weight gain in this population? And more importantly, should you prescribe it ASAP? Listen in as Dr. Rosenberg answers these questions and others. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 12 Metformin for Weight Gain in Youth on Atypical Antipsychotics

In this podcast, Dr. Jim Phelps discusses the issue of diagnosing bipolar disorder within the framework of a mood spectrum. How bipolar should a patient be before switching treatment strategies? Listen in for tips and practical takeaways to answer this question and guide decision making. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 52 “Cade’s Disease” and Beyond: Misdiagnosis, Antidepressant Use, and a Proposed Definition for Bipolar Spectrum Disorder

In this podcast, Dr. Schenck discusses zolpidem-induced sleeping disorder and eating disorder. Listen and find out important tips and considerations, such as this being more common in females, alerting bed partners, being careful with zolpidem doses over 10 mg, and more. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep-Related Eating Disorder Zolpidem-Induced Sleepwalking and SRED

Cariprazine may be a good option for pediatric patients with schizophrenia and bipolar I disorder. Listen as Dr. Rosenberg summarizes study findings, which may broaden your options with children and adolescents. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 11 Safety and Tolerability of Cariprazine in Pediatric Patients

This podcast explores medication associated with sleepwalking and sleep driving, as well as recommendations for clinicians when prescribing them to patients. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep-Related Eating Disorder Medication-Induced SRED, Sleepwalking, and Sleepdriving  

In this episode, we explore whether the olanzapine–samidorphan combination helps with psychosis while halting weight gain. We also look into the cost vs benefit of the combination as well as the metabolic side effects. Faculty: James Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 51 Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis

Can melatonin reduce the risk of suicidality, bodily injuries, falls, and accidents in children and adolescents? In this episode, we explore a study that delves into this question. Discover how sleep disturbances impact young individuals' health, development, cognitive skills, emotional regulation, and behavior. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 11 Melatonin Use and the Risk of Self-Harm and Unintentional Injuries in Youth

Do you know what sleep-related eating disorder (SRED) is and how it intertwines sleep and eating pathologically? In this episode, we delve into an in-depth analysis of SRED, elucidating its diagnostic criteria, key characteristics of the diagnosis, and some intriguing aspects related to this disorder. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Parasomnias Triggered by Sedative-Hypnotics: Sleepwalking and Sleep Related Eating Disorder Diagnosing Sleep-Related Eating Disorder (SRED)

This episode explores the controversial role of pimavanserin in treating psychosis in Parkinson's disease. How does it compare with quetiapine or clozapine? Sneak peek: All of these medications are effective, yet none distinctly surpasses the others. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 51 Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis

Pediatric bipolar disorder treatment has evolved significantly since 2005, moving beyond lithium to several FDA-approved treatments. However, the challenges remain: How do we choose the first-line treatment? How can we mitigate and monitor side effects? In this episode, we discuss the latest practice treatment algorithms for pediatric bipolar disorder. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 10 Psychopharmacologic Treatment Algorithms for Bipolar Disorder in Youth

Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests.  Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 49 Effect of Pharmacogenomic Testing for Drug–Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial

In this episode, we discuss the role of broad-spectrum micronutrients (BSMs) in managing symptoms of ADHD. We examine the rationale behind opting for alternative therapies for this condition and dissect the outcomes of an RCT involving BSMs for ADHD. Could micronutrients provide a comprehensive strategy for treating ADHD, thereby enhancing overall mental wellness? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Broad-Spectrum Micronutrients (BSM) for Mental Health: Context for Considering Micronutrient Treatment An Overview of Standard Treatment vs CAM for ADHD

Are you aware that a staggering 80% of ADHD patients report at least 1 side effect from their medication? In this episode, we discuss an analysis that seeks to answer an essential question: Can we predict medication nonadherence in adolescents and young adults with ADHD based on specific side effects? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 10 Reported Side Effects Associated With Medication Nonadherence Among Youth With ADHD

Did you know that your genes could affect how your brain processes vital nutrients? In this episode, we delve into fascinating research on micronutrient supplementation for mental disorders, such as ADHD. Discover how our genetic makeup might dictate our nutrient needs and how this can influence mental health outcomes. Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Broad-Spectrum Micronutrients (BSM) for Mental Health: Context for Considering Micronutrient Treatment Rationale for Micronutrient Supplementation in Mental Illness  

Could antipsychotic switching impact substance use in schizophrenia? In this episode, Dr. Jim Phelps explores the impact of antipsychotics on patients with schizophrenia and substance use disorder. He includes insights from national cohorts and clinical cases and delves into the potential effects of changing from risperidone to clozapine. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 49 Associations Between Antipsychotic Use, Substance Use, and Relapse Risk in Patients with Schizophrenia: Real-World Evidence From 2 National Cohorts

Dive into the fascinating world of nutrition's impact on mental health in our latest episode. We explore intriguing studies on the Mediterranean diet's potential to alleviate depressive symptoms. Can a shift in dietary habits truly improve mental health? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Broad-Spectrum Micronutrients (BSM) for Mental Health: Context for Considering Micronutrient Treatment Depression and Mediterranean-Style Diet

In this episode, we explore a pressing problem in pediatric psychiatry: The disparities in the use of pharmacologic restraints. How can we address these biases in our healthcare system? What role do behavioral interventions play in reducing the need for these measures? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 09 Disparities in Pharmacologic Restraint Use in Pediatric Emergency Departments

In this episode, we discuss the causes of clozapine-induced orthostasis. Although some patients may develop tolerance, it can limit titration and potentially obstruct patients from reaching the plasma level where they respond well to the medication. There are practical management strategies for orthostasis, including slow titration based on patient complaints and encouraging fluid intake, among others. Faculty: Jonathan Meyer, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Managing Some Unique Nonhematologic Adverse Effects of Clozapine Managing Clozapine-Related Orthostasis

In this episode, we discuss the potential of lavender extract, Silexan, as an alternative treatment for anxiety and insomnia with Dr. Jim Phelps. Is it truly a promising solution free from dependency and withdrawal symptoms or just an effective placebo? Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 48 Effect of Anxiolytic Drug Silexan on Sleep – A Narrative Review

In this episode, we explore a common yet severe side effect of clozapine: Constipation. Why does this drug cause such drastic changes in colonic transit times, and how can we manage it effectively? Faculty: Jonathan Meyer, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Managing Some Unique Nonhematologic Adverse Effects of Clozapine Managing Clozapine-Related Constipation

In this episode, we discuss a comprehensive study on the potential cardiovascular risks of ADHD medication. Although these medications pose minimal risk for those without preexisting conditions, there seems to be an elevated risk for those with preexisting cardiovascular diseases. Should we confidently prescribe these medications? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about Silver and Gold memberships here Earn 0.5 CMEs: CAP Smart Takes Vol. 09 Risk of Cardiovascular Diseases Associated With Medications Used in ADHD

In this episode, we delve into the problem of sialorrhea or excessive salivation in patients on clozapine. Why does this occur, and how can it be managed? Join us as Dr. Jonathan Meyer shares his expertise on this unique side effect. Faculty: Jonathan Meyer, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Managing Some Unique Nonhematologic Adverse Effects of Clozapine Managing Clozapine-Related Sialorrhea

Can a simple lab test guide our choice of antidepressants? Explore the intriguing link between inflammation, measured by C-reactive protein (CRP) levels, and the effectiveness of certain antidepressants in this episode. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 48 C-Reactive Protein Could Predict the Efficacy of SSRIs in Clinical Practice: A Cohort Study of Large Samples in the Real World

Could ketamine be the breakthrough we need in treating adolescent depression? Join us in this episode as we explore the potential of ketamine therapy and its rapid antidepressant effects. Also, learn how ketamine works, its safety profile, and why it's not quite ready for mainstream use in adolescents. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 08 Ketamine for Adolescent Depression

In this episode, we dive into the puzzling case of a 67-year-old man experiencing violent moving nightmares. Is it rapid eye movement sleep behavior disorder, frequent and recurring nightmares, night terrors, PTSD, or another parasomnia? Tune in as we explore potential diagnoses with our expert Dr. Carlos Schenck. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Parasomnias Triggered by Antidepressant Medications: REM SleepBehavior Disorder and Restless Legs Syndrome A Clinical Case and Exclusive Videos On RBD and RLS

In this episode, we delve into a new horizon in the management of acute agitation. We discuss dexmedetomidine, a drug that's been around since 1999, recently reformulated into a sublingual film and FDA approved for treating agitation associated with schizophrenia or bipolar I or II disorder. We explore the results from a recent randomized trial and its potential for transforming psychiatric care. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 47 Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

In this episode, we dive into rapid eye movement sleep behavior disorder (RBD). Did you know that RBD's prevalence is on par with schizophrenia in middle-aged and older adults? Tune in as we explore the prevalence, assessment, and management of RBD, a condition that is not only a sleep disorder but a potential harbinger of severe neurological conditions, like Parkinson's Disease and Dementia with Lewy Bodies. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Parasomnias Triggered by Antidepressant Medications: REM Sleep Behavior Disorder and Restless Legs Syndrome Prevalence, Assessment, and Management of RBD

In this episode, we dive deep into the effects of ADHD medication on anxiety and depressive symptoms in children and adolescents. Can these medications significantly exacerbate symptoms of anxiety or depression? Or do these symptoms arise more from the underlying condition of ADHD? We will delve into these critical questions and more through a thorough exploration of a comprehensive meta-analysis. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 08 Impact of ADHD Medications on Anxiety and Depression in Youth

In this episode, we delve deep into the diagnostic mysteries of RBD, the need for video polysomnography, and the mechanisms leading to RBD. Whether you are a veteran or new to the field, this episode promises to deepen your understanding of RBD. Faculty: Carlos Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Parasomnias Triggered by Antidepressant Medications: REM Sleep Behavior Disorder and Restless Legs Syndrome Diagnosing REM Sleep Behavior Disorder

Are we missing a vital piece in the schizophrenia treatment puzzle? In this episode, we explore the intriguing and controversial role of N-acetylcysteine (NAC) in schizophrenia. We dive deep into the evidence, the theories, and the ongoing debates about this seemingly simple over-the-counter supplement. Could NAC be the key to unlocking better outcomes for those with schizophrenia, or is it just another dead end? Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 47 Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

How can N-acetyl cysteine (NAC) and S-adenosyl methionine (SAMe) be effectively integrated into child and adolescent psychiatric treatment? In this episode, we dive deep into the world of NAC and SAMe and explore their potential applications, dosage, side effects, and more. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry Administration of N-Acetylcysteine and S-Adenosylmethionine in Children and Adolescents

How has the use of antipsychotics among children and adolescents been affected by the COVID-19 pandemic in the United States? In this episode, we delve into pandemic-induced trends in youth psychotropic prescriptions. Uncover how COVID-19 reshaped mental health services and psychopharmacology among young individuals. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 07 Psychotropic Prescriptions in Youth During COVID-19 Pandemic

Can nature’s remedies hold the key to mental well-being in our youth? In this episode, we delve into the potential uses and limitations of St. John’s wort and valerian in child and adolescent psychiatry and, most importantly, their evidence in treating psychiatric disorders in this population. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry St. John’s Wort and Valerian: Potential Indications in Children and Adolescents

Have you ever pondered the mystery behind the effectiveness of different SSRI dosing strategies for premenstrual dysphoric disorder (PMDD)? In this episode, we delve deep into the complex world of PMDD treatments, focusing on the intriguing comparison between intermittent luteal phase dosing and continuous dosing of serotonergic antidepressants. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 46 Intermittent Selective Serotonin Reuptake Inhibitors for Premenstrual Syndromes: A Systematic Review and Meta-Analysis of Randomized Trials

Have you ever wondered how natural remedies like omega-3 fatty acids might influence child and adolescent psychiatry? In this episode, we delve into the intriguing world of omega-3 fatty acids and their potential role in treating various psychiatric disorders in children and adolescents, such as major depressive disorder, bipolar disorder, ADHD, and ASD. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry Use of Omega-3 Fatty Acids in Children and Adolescents

 Have you ever wondered about the safety and effectiveness of ADHD medications in preschoolers? In this episode, we discuss a pioneering double-blind, fixed-dose study exploring the use of lisdexamfetamine in children aged 4–5 years. We delve into the nuances of this complex topic, from the increasing trend of psychotropic medication use in young children, to the unique characteristics that distinguish lisdexamfetamine from other amphetamine medications. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 07 Efficacy and Safety of Lisdexamfetamine in Preschool Children with ADHD

In this episode, we delve into the intriguing world of ginkgo biloba and its potential role in treating ADHD in children and adolescents. Can this ancient herbal remedy offer a valuable alternative or adjunctive therapy? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Natural Medications in Child and Adolescent Psychiatry Use of Ginkgo Biloba in Children and Adolescents

In this episode, we delve into the intriguing world of COVID-19's long-term effects in psychiatry. We explore a groundbreaking study that examines the duration of COVID-associated psychiatric disorders and variations in susceptibility by age. How long do these disorders persist, and are certain age groups more affected? Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 46 Neurologic and Psychiatric Risk Trajectories After SARS-CoV-2 Infection: An Analysis of 2-Year Retrospective Cohort Studies Including 1,284,437 Patients

In this episode, you'll discover the preferred second-generation antipsychotics for augmenting treatment for obsessive-compulsive disorder: Risperidone and aripiprazole. We discuss their effectiveness and important considerations when choosing between them. What factors should clinicians weigh when deciding on an augmentation strategy? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder Node 4: SSRI Augmentation With SGA

In this episode, we focus on the challenges faced in metabolic monitoring of youth receiving second-generation antipsychotics (SGAs), including the strategies to overcome these barriers and ensure the long-term health of young patients on SGAs. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 06 Barriers to Metabolic Monitoring of SGAs in Youth

In this episode, we delve into the potential outcomes after the first SSRI trial for OCD. With SSRIs being a first-line treatment, understanding response patterns is crucial. What course of action should be taken when patients exhibit significant symptom improvement, partial relief, or no response? Discover when to discontinue, switch, or augment treatment. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder Node 2: Potential Outcomes After the First Trial

In this episode, Dr. Richard Seeber and his special guests, Dr. Lorena Rodriguez and Dr. Paz Badia, discuss the topics covered in the APA Annual Meeting 2023, from technology in mental health practice to the use of cognitive–behavioral therapy for suicide prevention. Get ready to explore topics like ECT, ADHD, women's health, and much more. How can the integration of technology revolutionize mental health practice? Faculty: Paz Badia, M.D. and Lorena Rodríguez, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here

In this episode, we delve into the fascinating world of microdosing psilocybin. A recent randomized trial examined the effects of microdosing using various outcome measures. Surprisingly, the acute effects were significantly more intense for the active dose but only when participants correctly identified their experimental condition. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 45 Microdosing With Psilocybin Mushrooms: A Double-Blind Placebo-Controlled Study

What factors should clinicians consider when choosing an SSRI for treating patients with OCD? In this episode, we dive into the first-line treatment for OCD: SSRIs. Discover the most effective SSRIs for treating OCD, recommended doses, and potential adverse effects. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder Node 2: First-Line Treatment: SSRIs

Are there any particular situations where nonstimulant medications may be especially effective for ADHD? In this episode, we discuss nonstimulant treatments for ADHD. Although stimulants are commonly used for ADHD, nonstimulant options like atomoxetine, viloxazine, clonidine, and guanfacine have been FDA approved and can be equally effective in certain populations. Listen in as we share clinical pearls on how to tailor treatments for each patient's unique needs. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about Silver and Gold memberships here Earn 0.5 CMEs: CAP Smart Takes Vol. 06 Nonstimulant Treatments for ADHD

In this episode, we share insights into the comorbidities and other considerations that can impact the treatment algorithm for OCD. From the risks of medication use in pregnant women, to the challenges of treating OCD in patients with comorbid bipolar disorder, this episode provides valuable clinical pearls for clinicians looking to improve their approach to treating OCD. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Algorithm for the Pharmacotherapy of Obsessive-Compulsive Disorder OCD Comorbidities and Other Circumstances: Variations in the Treatment Algorithm

In this episode, we discuss rapid cycling bipolar disorder and its treatment, focusing on the use of the combination of lamotrigine and lithium. We also highlight the importance of checking thyroid status and tapering antidepressants in patients with rapid cycling. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 45 Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-Analysis

In this episode, we discuss the potential use of melatonin as a safe and effective pharmacotherapy for sleep disturbances in children with ADHD and ASD. Did you know that up to 80% of children with ASD experience sleep disorders? Listen in to learn how melatonin can help improve sleep onset and duration in these patients. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents Potential Indications of Melatonin and Secretin in Children and Adolescents  

Which medications are safe and effective for treating nonsuicidal self-injury (NSSI) in children and adolescents? In this episode, we discuss the use of psychotropic medications in treating NSSI, which is becoming increasingly common in this population and can predict future suicide attempts. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 05 Psychotropic Drugs for Treating Nonsuicidal Self‑Injury in the Youth

This episode discusses D-cycloserine’s potential indications and administration in children and adolescents, including the evidence for anxiety disorders, OCD, ASD, and PTSD. It also mentions the dosage, administration, benefits, and side effects of D-cycloserine in youth. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents D-Cycloserine: Potential Indications and Administration in Children and Adolescents

Antidepressants are commonly used to treat depression, but how effective are they? In this episode, we discuss the concept of the minimal clinically important difference (MCID) and how it can be applied to assess antidepressant efficacy in treating depression. Specifically, knowing MCID estimates helps to shed light on recent controversies regarding antidepressant efficacy. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 44 Estimates of the Minimal Important Difference to Evaluate the Clinical Significance of Antidepressants in the Acute Treatment of Moderate-To-Severe Depression - Part 2

What is the role of memantine in pediatric populations? This episode discusses memantine’s potential indications and administration in children and adolescents, an explanation of the theory of glutamatergic dysregulation, and the evidence of memantine for ASD, OCD, and mood disorders. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents Memantine: Potential Indications in Children and Adolescents

In this episode, we examine the tolerability, safety, and effectiveness of low-dose olanzapine in adolescents with anorexia nervosa (AN). Learn about the potential benefits and risks of using olanzapine in AN patients and the importance of a multidisciplinary approach in treating this challenging population. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 05 Low-Dose Olanzapine for Treating Adolescents With Anorexia Nervosa

In this episode, we discuss the potential uses and challenges of naltrexone in children and adolescents while addressing the limited and conflicting evidence. We also examine the dosage, side effects, and important considerations for using naltrexone in young populations. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Atypical Psychopharmacologic Strategies for Children and Adolescents Naltrexone: Potential Indications and Administration in Children and Adolescents

Would a slower lamotrigine titration rate decrease the likelihood of developing the dreaded lamotrigine-associated rash? This episode discusses the possible advantages of slower lamotrigine titration rates, tips for managing benign rashes, and when to rechallenge lamotrigine. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 44 Impact of Selected Initial Titration Schedules on Safety and Long-Term Effectiveness of Lamotrigine for the Treatment of Mood Disorders

In this episode, we dive into a topic that's especially relevant for those working with older adults: The use of benzodiazepines and sedative-hypnotics. We explore the unique considerations of prescribing these medications to geriatric patients and the importance of deprescribing them when possible. Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Updates on Geriatric Psychopharmacology Considerations for Using Benzodiazepines and Benzodiazepine Receptor Agonists in the Geriatric Population

In this episode, we delve into lithium's efficacy and potential long-term effects in younger patients and what clinicians should carefully monitor in this population. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 04 Long-Term Effects of Lithium Use on Children and Adolescents

Are mood stabilizers the right choice for elderly patients? This episode discusses key insights about using mood stabilizers in the geriatric population, including side effects and monitoring for lithium, valproic acid, lamotrigine, carbamazepine, and gabapentinoids. Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Updates on Geriatric Psychopharmacology Considerations for Using Mood Stabilizers in the Geriatric Population

Do you have a patient suffering from postpartum depression? In this episode, we discuss a new study on light therapy as a potential treatment for postpartum depression, including the response rate, adverse effects, and effects on sleep quality. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 43 Efficacy of Bright Light Therapy in Perinatal Depression: A Randomized, Double-Blind, Placebo-Controlled Study

This episode discusses some strategies for starting antidepressants in the elderly, the important role of titrating doses, the efficacy of SSRIs, the side effects and drug–drug interactions of different medications, and clinical tips for using SSRIs and SNRIs in this population. Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Updates on Geriatric Psychopharmacology Using SSRIs and SNRIs in the Geriatric Population

Is duloxetine a viable option for youth with MDD? In this episode, we discuss the need for additional medication options in youth with depression as well as an RCT of duloxetine to assess its efficacy and a label extension trial to evaluate its long-term safety. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 04 Efficacy and Safety of Duloxetine in Children and Adolescents With MDD in Japan

What are the most common challenges when prescribing psychotropics to older adults? This episode discusses the challenges in prescribing psychotropics to the geriatric population, such as poor medication adherence and the risks of inappropriate prescribing. It also introduces a clinical case and emphasizes the importance of medication reconciliation. Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Updates on Geriatric Psychopharmacology Challenges in Prescribing Psychotropics in the Geriatric Population and Mrs. M’s Case

In this episode, we discuss an updated review of 11 studies that seek to evaluate the effect of antidepressants on the risk of hip and vertebral bone fractures. Although the overall effect size seems large, the absolute risk increase might be small. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 43 Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis

Are antidepressants effective for managing explosive behavior? In this episode, we discuss the efficacy of antidepressants and mood stabilizers for managing explosive behavior, including some proposed doses of lithium and divalproex sodium, and the indications for using antidepressants. Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents Antidepressants and Mood Stabilizers for Managing Explosive Behavior

In this episode, we discuss a meta-analysis that included 6 million patients to assess whether pharmacotherapy increases the risk of substance use or misuse, specifically the risk of using stimulant medications in children with ADHD. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Smart Takes Vol. 03 Impact of Pharmacotherapy of Childhood-Onset Psychiatric Disorders on the Development of Substance Use Disorders

In this episode, we discuss the SGAs with the most evidence for explosive behavior, their side effects, and monitoring recommendations. We also address the reasons for considering other SGAs and clarify which FGA has the most evidence for aggression. Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents First- and Second-Generation Antipsychotics for Managing Explosive Behavior

Should we start prescribing metformin to our patients on clozapine? In this episode, we discuss several articles on the efficacy of clozapine in preventing clozapine-induced weight gain, including some evidence on when metformin is more effective. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 42 Metformin for the Prevention of Clozapine-Induced Weight Gain: A Retrospective Naturalistic Cohort Study

In this episode, we discuss the management of acute aggression in children and adolescents, including therapeutic support for explosive behavior, psychosocial crisis management techniques, and the medications used for acute aggression. Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents Management of Acute Aggression in Children and Adolescents

In this episode, we discuss whether early nonresponse in adolescents with first-episode psychosis predicts longer-term nonresponse and nonremission. We also explain when it is most likely that symptom improvement occurs and some other considerations when there is nonresponse. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 03 Early Antipsychotic Nonresponse as a Predictor of Nonresponse in Adolescents With Psychosis

In this episode, we discuss the differential diagnosis of explosive behavior in children and adolescents, including the differences in these behaviors when they are associated with mood or anxiety disorders and disruptive behavior disorders. Faculty: Carrie Vaudreuil, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Managing Explosive Behavior in Children and Adolescents Management of Acute Aggression in Children and Adolescents

In this episode, we discuss the long-term follow-up of psychosis and schizophrenia in children and adolescents, including predictors of poor long-term outcomes and the comorbidities associated with schizophrenia in adults. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Publication Title Long-Term Follow-Up of Psychosis and Schizophrenia in Children and Adolescents

In this episode, we discuss a recent systematic umbrella review of the evidence behind the serotonin theory of depression and the controversy this review has generated. We explore the evidence presented regarding the interplay between serotonin and depression and present concrete steps to address several concerns generated by the review. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 42 The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence

Is there an association between SSRIs and type 2 diabetes in children and adolescents? In this episode, we discuss whether there is an association. We also explain whether there is an intraclass risk among different SSRIs. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Smart Take Vol. 02 SSRIs and Risk of Type 2 Diabetes in Children and Adolescents

In this episode, we discuss additional clinical tips for treating schizophrenia in children and adolescents, including the considerations for selecting antipsychotics, recommendations for nonresponse, and when to use clozapine. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Psychosis and Schizophrenia in Children and Adolescents Additional Clinical Tips for Treating Schizophrenia In Children and Adolescents

In this episode, we review the current literature on the association between exercise and the risk for depression. Specifically, how much physical activity is associated with a lower risk for depression? We also discuss the World Health Organization recommendations for the ideal range of physical activity. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 41 Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-Analysis

In this episode, we discuss treatment options for managing psychosis and schizophrenia in children and adolescents, including the FDA-approved antipsychotics for this population. We also explain medication dosing guidelines and monitoring recommendations.  Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychosis and Schizophrenia in Children and Adolescents Treatment of Psychosis and Schizophrenia in Children and Adolescents: Antipsychotic Dosing, Monitoring, and Side Effects

Are antidepressants in adolescent depression associated with an increased risk for suicidality? In this episode, we discuss the particularities of adolescent depression, including some statistics and the risk of suicide when using antidepressants in this population. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Smart Take Vol. 02 Depression in Adolescents

In this episode, we discuss the diagnosis of psychotic symptoms in children and adolescents, including the differences between primary and secondary psychosis and the rating scales for assessing these symptoms.  Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychosis and Schizophrenia in Children and Adolescents Diagnostic Evaluation of Psychotic Symptoms in Children and Adolescents

Can L-methylfolate help in depression treatment? Should we indicate it to all patients with depression? In this episode, we discuss the metabolic pathways for folic acid, when to indicate L-methylfolate, and when to perform genetic testing for methyltetrahydrofolate reductase (MTFR) enzymes.  Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 41 The Potential Use of Folate and Its Derivatives in Treating Psychiatric Disorders: A Systematic Review

Antipsychotics or cholinesterase inhibitors for BPSD? This episode discusses the evidence of antipsychotics and cholinesterase inhibitors for BPSD, including the risks of using antipsychotics in elderly patients. We also provide recommendations for treating patients with Parkinson’s disease and Lewy body dementia. Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia Antipsychotics and Cholinesterase Inhibitors for BPSD

What are the safest and most effective medications for depression in youth with bipolar disorder? In this episode, we compare the response rates of quetiapine, olanzapine, and lurasidone for bipolar depression in youth. This episode also explains the differences in metabolic side effects and discusses the limitations of this study.  Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Smart Take Vol. 01 Efficacy and Safety of SGAs in Youth With Bipolar Depression

This episode discusses the pharmacologic treatments for BPSD, including the indications for using psychotropic medications as first-line treatment. It also explains when medications are ineffective and when to use them as a temporary measure. Faculty: Lauren Gerlach, D.O. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia Overview of Pharmacologic Treatment for BPSD

What are FIASMA psychotropics? What do they have to do with COVID-19? In this episode, we discuss a recent study that compared rates of severe illness among patients who, when admitted for COVID-19, were or were not taking a FIASMA—a functional inhibitor of acid sphingomyelinase activity. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 40 Association Between FIASMA Psychotropic Medications and Reduced Risk of Intubation or Death in Individuals With Psychiatric Disorders Hospitalized for Severe COVID-19: An Observational Multicenter Study

Are antipsychotics the answer to the chaos of dementia? In this episode, we discuss the pharmacologic and nonpharmacologic treatment approaches to address BPSD, including the risks of using antipsychotics and the causes of death related to their use.  Faculty: Lauren Gerlach, D.O.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia Pharmacologic and Nonpharmacologic Treatment Approaches

In this episode, we discuss a recent RCT on using brexpiprazole to treat borderline personality disorder. Is it safe and effective? Could brexpiprazole be the magic bullet we were waiting for?  Faculty: Jim Phelps, M.D.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 40 A Double-Blind Placebo-Controlled Study of Brexpiprazole for the Treatment of Borderline Personality Disorder

This episode discusses the patient factors underlying BPSD, such as neurodegeneration, acute medical issues, medication changes, pain, and psychiatric diagnoses. It also explains caregiver and environmental factors and the concept of the “broken brain.”  Faculty: Lauren Gerlach, D.O.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Management of Behavioral and Psychological Symptoms of Dementia Understanding Patient, Caregiver, and Enviromental Factors

Is it safe to use stimulants in preschool children with ADHD? In this episode, we discuss the long-term symptom control and safety of an ER methylphenidate compound in preschool children 4 to Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Smart Take Vol. 1 Long-Term Treatment With Extended-Release Methylphenidate Treatment in Younger Children

How to determine whether hepatic impairment can affect drug metabolism? This episode discusses practical considerations when prescribing psychotropic medications for patients with hepatic issues. It also clarifies dosing considerations for specific medications, such as clozapine and valproate, in the context of patients with hepatic issues.  Guest: Jonathan Meyer, M.D.  Interviewer: Mohan Gautam, M.D.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Use of Psychotropics in Patients With Hepatic Issues - Interview with Jonathan M. Meyer, M.D.

How to titrate clozapine in inpatients and outpatients? In this episode, we discuss important considerations for switching to clozapine, including the indications and clinical scenarios for using it. This episode also explains precautions while titrating clozapine and how to reduce the preswitch antipsychotic.  Faculty: Brian Miller, M.D.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science Important Considerations for Switching to Clozapine

In this episode, we discuss the interventions found to be efficacious in youth with ADHD. Specifically, would treatment with stimulants be effective at reducing irritability in youth with ADHD?  Faculty: Jim Phelps, M.D.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 39 A Mini-Review of Pharmacologic and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD

This episode discusses antipsychotic switching from oral antipsychotics to LAIs, including the factors to consider when titrating antipsychotics and establishing PO tolerability before switching to an LAI.  Faculty: Brian Miller, M.D.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science Types of Antipsychotic Switching: Between PO Agents and From PO to LAI

In this episode, we discuss a systematic review and network analysis that compares 11 medications for treating severe agitation in the emergency department. Which medications have been shown to work best?  Faculty: Jim Phelps, M.D.  Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 39 Rapid Tranquilization of the Agitated Patient in the Emergency Department: A Systematic Review and Network Meta-Analysis

Which is the preferred strategy for switching from one antipsychotic to another? This episode discusses strategies for antipsychotic switching: Abrupt, cross-taper, taper, and plateau cross-taper switch.                               Faculty: Brian Miller, M.D. Hosts: Jessica Diaz, M.D., Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science Strategies for Antipsychotic Switching  

Are there FDA-approved medications for eating disorders? In this episode, we discuss management strategies for eating disorders, including the use of FDA-approved medications, the importance of cognitive–behavioral interventions, and the need to reduce stigma in these disorders.  Guest: Timothy Brewerton, M.D.  Interviewer: Wegdan Rashad, M.D.  Hosts: Jessica Diaz, M.D.; Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CMEs: The Psychopharmacology of Feeding and Eating Disorders - Interview with Timothy Brewerton, M.D.,DLFAPA, FAED, DFAACAP, CEDS-S

What are the contraindications to antipsychotic switching? This episode discusses the relative contraindications of antipsychotic switching, including recent recovery from an acute psychotic episode, current stability on an LAI, and history of violence or severe symptoms.  Faculty: Brian Miller, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: Antipsychotic Switching: Intersection of Art and Science Relative Contraindications to Antipsychotic Switching

Why do patients stop clozapine?  This episode discusses clozapine discontinuation rates and reasons for doing so among patients who later recommenced clozapine therapy.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 38 Demographic and Clinical Characteristics of Patients Who Recommence Clozapine Following Therapy Interruptions

Sharpen your clinical skills with a clinical case of an adolescent girl with OCD. This episode also reviews the progression and consequences of the patient’s symptoms, the diagnosis, and the best treatment options for improving her symptoms.  Faculty: David Rosenberg, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: OCD in Children and Adolescents Assessing and Treating Jane

In this episode, Dr. Phelps discusses a study on the efficacy and safety of mirtazapine for treating agitation in patients with dementia. Would prescribing mirtazapine be worth the risk?  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 38 Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD): A Randomised, Double-Blind, Placebo-Controlled Trial    

Can we use clomipramine in children? This episode discusses tips for clinicians treating pediatric OCD, follow-up on pediatric OCD symptoms into adulthood, and treatment response in OCD. It also reviews the use of clomipramine for treatment-resistant OCD and its requirements and precautions. Faculty: David Rosenberg, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: OCD in Children and Adolescents Clinical Tips for Treating Pediatric OCD, Long-Term Follow-Up, and Treatment-Resistant OCD

How should we treat patients with bipolar disorder and comorbid GAD? In this episode, Dr. David Osser discusses an evidence-based treatment algorithm for the treatment of generalized anxiety disorder. He also clarifies common clinical concerns, such as treating GAD in patients with comorbid conditions and treatment resistance.  Guest: David Osser, M.D.  Interviewer: Mohan Gautam, D.O.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: GAD Psychopharmacology Algorithm -Interview with David Osser, M.D. Psychopharmacology Algorithms from Psychopharmacology Algorithms Project at the Harvard South Shore Psychiatry Residency Training Program

What are the FDA-approved medications for pediatric OCD? This episode discusses the guidelines for the management of pediatric OCD, including the treatment for mild, moderate, and severe OCD symptoms, as well as the recommended treatment for remission and maintenance, partial response, and nonresponse. It also examines medication dosing guidelines and FDA-approved medications.  Faculty: David Rosenberg, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: OCD in Children and Adolescents Guidelines for the Management of Pediatric OCD

Can ketamine be an effective adjunctive treatment to sustain abstinence from alcohol? In this episode, Dr. Phelps discusses a double-blind, placebo-controlled trial of adjunctive ketamine with mindfulness psychotherapy for treating alcohol use disorder.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 37 Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder

How to untangle pediatric OCD from ASD and GAD? This episode discusses pediatric OCD and its comorbidities: Depression, GAD, and ASD. It includes a discussion on the differences in concerns between OCD and GAD, the assessment of primary and secondary depressive symptoms, and the differences between ASD and OCD rituals.  Faculty: David Rosenberg, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: OCD in Children and Adolescents Pediatric OCD Comorbidity With Depression, Anxiety Disorders, and ASD

Have you ever imagined using rTMS for patients who struggle to quit smoking? This episode discusses a double-blind RCT that assessed the efficacy of rTMS in patients with tobacco use disorder who had at least 1 prior failed attempt to quit. Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 37 Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: A Pivotal Multicenter Double‐Blind Randomized Controlled Trial

Learn some of the recommendations from the Handbook of Good Psychiatric Management for Borderline Personality Disorder.  This episode addresses the clinical approach and drug management in the good psychiatric management of BPD.  Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments Good Psychiatric Management for BPD  

How do you distinguish obsessive-compulsive and related disorders from habits? In this episode, we discuss the varying presentations of OCRDs and challenges in their management, including practical recommendations for psychopharmacologic management.  Guest: Robert Hudak, M.D.  Interviewer: Wegdan Rashad, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Obsessive-Compulsive and Related Disorders - Interview with Robert Hudak, M.D.

What other medications can we offer to our patients with BPD? This episode discusses some novel medication approaches used in borderline personality disorder, including omega-3 fatty acids, methylphenidate, clonidine, doxazosin, memantine, and oxytocin.  Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments Omega-3 Fatty Acids, Methylphenidate, Clonidine, Doxazosin, Memantine, and Oxytocin for BPD

Is lithium really effective in patients with a high risk of suicide? In this episode, Dr. Phelps discusses a randomized clinical trial that assessed the efficacy of adding lithium to an existing medication regimen for reducing the rate of suicide-related events in veterans with bipolar disorder and depression.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 36 Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder

Are mood stabilizers effective for borderline personality disorder? This episode discusses the use of lamotrigine and lithium in BPD patients, including possible benefits, concerns, and recommendations regarding these medications.  Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments Mood Stabilizers for BPD: Lamotrigine and Lithium

Should we target anxiety disorders and sleep-related problems simultaneously? In this episode, Dr. Phelps discusses a narrative review to provide an overview of the evidence of the associations between anxiety disorders and sleep-related problems in children and adolescents.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 36 Treatment Implications of Sleep‑Related Problems in Pediatric Anxiety Disorders: A Narrative Review of the Literature

This episode discusses the use of antipsychotics in patients with borderline personality disorder, including specific information on quetiapine and clozapine and some tips regarding the use of antipsychotics in these cases.               Faculty: Paul Links, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments Antipsychotics for BPD

Which medications can we offer for alcohol use disorder? This episode will offer practical tips for selecting and initiating medications for managing patients with at-risk drinking and alcohol use disorder. Guest: Joji Suzuki, M.D. Interviewer: Wegdan Rashad, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: What Clinicians Need to KnowAbout Alcohol Use Disorder -Interview with Joji Suzuki, M.D.  

This episode discusses the evidence and benefits of topiramate and stimulant replacement therapy for cocaine use disorder. It also addresses the use of these medications when there are comorbidities, such as alcohol use disorder and ADHD.  Faculty: Andrew Saxon, M.D.  Hosts: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder Topiramate and Methylphenidate for Cocaine Use Disorder and Its Comorbidities

In this episode, we discuss the problem of pre-existing mood disorders increasing the risk of hospitalization and death among people infected with COVID-19. Why does this occur? Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 34 Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death  

This episode discusses the evidence of mirtazapine, bupropion, and naltrexone for stimulant use disorder. Are these promising treatments? Are they really effective?  Faculty: Andrew Saxon, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder Antidepressants and Naltrexone for Methamphetamine Use Disorder

Can we use ketamine as a maintenance treatment for MDD? In this episode, Dr. Phelps discusses CANMAT’s recommendations for the use of ketamine for MDD. Faculty: Jim Phelps, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 35 The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults With Major Depressive Disorder

Can methylphenidate help amphetamine and methamphetamine use disorder? This episode discusses stimulant replacement therapies for methamphetamine and amphetamine use disorder. This includes the possible use of MPH in patients with underlying ADHD.  Faculty: Andrew Saxon, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder

What is the first-line treatment for premenstrual mood syndromes? In this episode, Dr. Lauren Osborne discusses premenstrual mood syndromes and offers valuable insights regarding their management. She also discusses novel medications, such as brexanolone and drospirenone.  Guest: Lauren Osborne, M.D.  Interviewer: Wegdan Rashad, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Premenstrual Mood Syndromes -Interview with Lauren Osborne, M.D.

This episode discusses the course and prognosis for stimulant use disorder as well as how to diagnose and assess this disorder. It also explains the loss of control over stimulant use, dysfunctional behaviors, co-occurring psychiatric disorders, and medical side effects.  Faculty: Andrew Saxon, M.D. Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder Stimulants Use: Course, Assessment, and Diagnosis

Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum depression.  Faculty: Jim Phelps, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 35 Effect of Zuranolone vs Placebo in Postpartum Depression  

How long should we continue antipsychotic treatment in FEP? This episode discusses the long-term treatment of FEP, including the duration of antipsychotic treatment and the effects of dose reduction, the pros and cons of antipsychotic treatment, and the importance of collaborative treatment.  Faculty: Stephen Marder, M.D.  Host: Jessica Diaz, M.D. Learn more about our memberships here Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis Long-Term Treatment of FEP

In this episode, Dr. Phelps discusses the recent literature on brain volume changes after first-episode psychosis. What causes brain volume reductions—the illness or antipsychotics?  Faculty: Jim Phelps, M.D.  Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 34 The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies    

Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness? This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early metabolic changes.  Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D. Learn more about our memberships here Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis Health Concerns for First-Episode Patients  

This episode discusses treatment-resistant early psychosis, including treatment with LAIs and the use of clozapine for treatment-resistant cases.  Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D. Learn more about our memberships here Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis Psychopharmacology for People With Treatment-Resistant Early Psychosis